sri 62-834 has been researched along with Acute Promyelocytic Leukemia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dive, C; Watson, JV; Workman, P | 1 |
| Donaldson, J; Lohmeyer, M; Workman, P | 1 |
2 other study(ies) available for sri 62-834 and Acute Promyelocytic Leukemia
| Article | Year |
|---|---|
Multiparametric flow cytometry of the modulation of tumor cell membrane permeability by developmental antitumor ether lipid SRI 62-834 in EMT6 mouse mammary tumor and HL-60 human promyelocytic leukemia cells.
Topics: Animals; Antineoplastic Agents; Azepines; Cell Division; Cell Membrane Permeability; Flow Cytometry; Furans; Humans; Hydrogen-Ion Concentration; Leukemia, Promyelocytic, Acute; Mammary Neoplasms, Animal; Mice; Phospholipid Ethers; Platelet Activating Factor; Time Factors; Triazoles; Tumor Cells, Cultured | 1991 |
Platelet-activating factor (PAF) antagonist WEB 2086 does not modulate the cytotoxicity of PAF or antitumour alkyl lysophospholipids ET-18-O-methyl and SRI 62-834 in HL-60 promyelocytic leukaemia cells.
Topics: Antineoplastic Agents; Azepines; Calcium; Cell Survival; Dose-Response Relationship, Drug; Drug Interactions; Furans; Humans; Leukemia, Promyelocytic, Acute; Phospholipid Ethers; Platelet Activating Factor; Structure-Activity Relationship; Triazoles; Tumor Cells, Cultured | 1991 |